Initiates 2026 guidance, anticipating another record year BELGRADE, Mont., March 05, 2026 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported financial results for the fourth quarter and year ended December 31, 2025, including positive net income for the full year. Highlights:Revenue for 2025 grew 25% to $122.8 million, surpassing the company’s increased guidance range Positive Net Income for 2025 was $4.1 million, with adjusted EBITDA increasing 21% from 2024 to $45.3 million Completed $331.5 million financing package, including debt refinancing and a $100.0 million delayed draw facility, to bolster financial flexibility and fund strategic fleet expansion amid rising demand...

Thursday, March 05, 2026 PRESS RELEASE: Annual Accounts 2025Good resilience of Savencia in a difficult dairy context   Approval of the merger between Savencia Fromage & Dairy and Savencia Gourmet’s Chocolate activities to accelerate the development of Premium Foodservice   Completion of the acquisition of Quata in BrazilKey figures in €M   31/12/25   % CA   31/12/24   % CA   Changes in %Total Structure Change & IAS 29 Growth OrganicSales 6 957   7 140   -2.6 0.2 -4.3 1.6– Cheese products 4 017 57.7 4 055 56.8 -1.0 0.0 -0.9 0.0– Other dairy products 3 184 45.8 3 328 46.6 -4.3 0.3 -8.4 3.7– Unallocated -245 -3.5 -244 -3.4        Current Operating Profit 210.5 3.0 232.3 3.3 The audit procedures have been carried out and the audit report relating to certification is currently...

Date: 5 March 2026 Release: After closing of Euronext Please open the following link to read the full report including annexes:AttachmentFULL PRESS RELEASE

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2025. “Our team has made tremendous progress recently in the global Phase 2 B-SUPREME study of pevifoscorvir sodium,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “With the completion of the planned enrollment in the HBeAg- cohort, we are continuing to enroll participants in the HBeAg+ cohort and look forward to the interim analyses in the first and second half of 2026. Additionally, the Phase 2 B-SUPREME study may demonstrate...

WILMINGTON, Del., March 05, 2026 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), provider of remote monitoring and control solutions for critical infrastructure assets, announced results for its fourth quarter (Q4’25) and full-year ended December 31, 2025. Acorn will hold an investor call today at 11 a.m. ET (details below).Summary Financial Results ($ in thousands)   Q4’25     Q4’24   Change     2025     2024   ChangeMonitoring revenue $ 1,411   $ 1,203     +17.3 %   $ 5,560   $ 4,553     +22.1 %Hardware revenue $ 966   $ 2,326     -58.5 %   $ 5,918   $ 6,433     -8.0 %Total revenue(1) $ 2,377   $ 3,529     -32.6 %   $ 11,478   $ 10,986     +4.5 %Gross margin   80.1 %   72.4 %   +770 bps     76.8 %   72.8 %   +400 bpsNet income to stockholders (2) $ 1,074   $ 5,233     -79.5 %   $ 2,510   $ 6,294     -60.1 %Diluted...

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) in the Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), expansion cohorts are now open and enrolling patients with these tumor types; based on an additional response in a patient with Hodgkin lymphoma, a further expansion cohort of patients with Hodgkin lymphoma will begin shortly. The IND application for CTX-10726 (PD-1 x VEGF-A bispecific antibody) received FDA clearance...

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights:CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed $91.2 million...

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A; TSX:STCK.WT.B) today announced its financial results for the year ended December 31, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. FINANCIAL SUMMARYBook Value per Share (BVpS): $15.35, compared to $12.29 as at December 31, 2024 (+24.9% increase) Total Book Value: $202 millionThe increase in Book Value during the year reflects strong performance across core portfolio holdings and disciplined capital deployment across late-stage private market opportunities. PORTFOLIO COMPANY HIGHLIGHTS SpaceXCompleted a tender offer transaction valuing the company at US$800 billion, reflecting continued investor demand and confidence in its long-term growth trajectory Subsequent...

Fourth Quarter Highlights and Recent DevelopmentsFourth quarter revenue of $32.9 million, up 26% q/q, 148.9% y/y, in line with target guidance Gross margin improvement of approximately 1,500 basis points q/q and 4,900 points y/y Awarded 1GW supply agreement with leading developer for 1P and 2P trackers in U.S. Secured 840MW supply agreement with Lubanzi for 1P and 2P trackers in South AfricaAUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, today announced financial results for the fourth quarter that ended December 31, 2025. “I’m pleased to share that our fourth quarter results came in at the high-end of our target ranges and we continued to position the company for long-term success,” said Yann Brandt, President and Chief Executive Officer of FTC Solar....

Virtuix: Pioneering Movement in AI-Generated WorldsNet Sales up 41% to $3.0 Million in Nine Months Ended December 31, 2025 Gross Margin Increased by 46% and Operating Expenses Decreased by 45% Strategic Collaboration with Meta and Global Expansion Accelerate Omni One Adoption and Scale AI-Enabled Defense Training and Enterprise Applications Advance Multi-Use Growth Strategy Virtuix Rang the Nasdaq Closing Bell on March 4, 2026 Management to Host Conference Call Today at 8:30 a.m. Eastern Time AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX) (the “Company”), a leading developer of full-body virtual reality systems, today reported financial and operational results for the three and nine months ended December 31, 2025. Figures presented herein are approximate and have been minimally...